Coronavirus Update: Sanofi And GSK’s ‘Tortoise’ Joins Hares In Vaccine Race

Plus: Japan Pledges Support For Covax Initiative

Initial results from the study are expected in early December 2020, which would allow the start of a Phase III trial before the end of the year.

Sanofi - GSK
Sanofi and GSK's track record in vaccines and manufacturing capacity could count in the longer term. • Source: Shutterstock

Sanofi and GlaxoSmithKline plc have announced the start of the Phase I/II trial for their adjuvanted COVID-19 vaccine – a relative latecomer to the field but which has the potential to play a central role in tackling the pandemic in 2021.

Paul Hudson, Sanofi’s CEO has dubbed the vaccine the ‘tortoise’ in the race against the speedy ‘hare’ candidates from companies...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip